{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:11:49Z","timestamp":1784607109055,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.heliyon.2022.e09925","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T12:03:48Z","timestamp":1657368228000},"page":"e09925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Nose to brain delivery of nanosuspensions with first line antiviral agents is alternative treatment option to Neuro-AIDS treatment"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-9810","authenticated-orcid":false,"given":"Smita P.","family":"Kakad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti D.","family":"Gangurde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay J.","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali G.","family":"Mundhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2022.e09925_bib1","series-title":"UNAIDS Report on the Global AIDS Epidemic","author":"Global report","year":"2017"},{"issue":"18","key":"10.1016\/j.heliyon.2022.e09925_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"Antinori","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.heliyon.2022.e09925_bib3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(12)70098-4","article-title":"HIV-associated opportunistic infections of the CNS","volume":"11","author":"Tan","year":"2012","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09925_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-1293.2012.01033.x","article-title":"Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital","volume":"14","author":"Riveiro-Barciela","year":"2013","journal-title":"HIV Med."},{"issue":"4","key":"10.1016\/j.heliyon.2022.e09925_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.53879\/id.58.04.11888","article-title":"Formulation and optimization of ritonavir nasal nanosuspension for brain targeting","volume":"58","author":"Mulam","year":"2021","journal-title":"Indian Drugs"},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09925_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/0973-8398.56293","article-title":"Nanosuspension technology and its applications in drug delivery","volume":"3","author":"Arunkumar","year":"2014","journal-title":"Asian J. Pharm."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09925_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jac\/dkh357","article-title":"Lopinavir\/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen","volume":"54","author":"Isaac","year":"2004","journal-title":"J.\u00a0Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.heliyon.2022.e09925_bib8","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1211\/0022357023691","article-title":"Nanosuspensions: a promising drug delivery strategy","volume":"56","author":"Patravale","year":"2004","journal-title":"J.\u00a0Pharm. Pharmacol."},{"issue":"8","key":"10.1016\/j.heliyon.2022.e09925_bib9","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/jps.22587","article-title":"Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption","volume":"100","author":"Sun","year":"2011","journal-title":"J.\u00a0Pharmaceut. Sci."},{"issue":"1-2","key":"10.1016\/j.heliyon.2022.e09925_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2010.09.041","article-title":"Optimization of formulation and process variable of Nanosuspension: an industrial perspective","volume":"402","author":"Singare","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.heliyon.2022.e09925_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e08368","article-title":"Nose to brain delivery of Efavirenz nanosuspension for effective neuro AIDS therapy: in-vitro, in-vivo and pharmacokinetic assessment","volume":"7","author":"Kakad","year":"2021","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09925_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/45.1.77","article-title":"Preparation of a clofazimine Nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection","volume":"45","author":"Peters","year":"2000","journal-title":"J.\u00a0Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09925_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1081\/DDC-52182","article-title":"Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound","volume":"31","author":"Langguth","year":"2005","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09925_bib14","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.2147\/IJN.S35329","article-title":"Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study","volume":"7","author":"Alam","year":"2012","journal-title":"Int. J. Nanomed."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09925_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/10717544.2013.838014","article-title":"Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting","volume":"21","author":"Mahajan","year":"2014","journal-title":"Drug Deliv."},{"issue":"7","key":"10.1016\/j.heliyon.2022.e09925_bib16","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3109\/10717544.2013.878857","article-title":"Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization","volume":"22","author":"Shah","year":"2015","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09925_bib17","first-page":"161","article-title":"Design and characterization of zaltoprofen Nanosuspension by precipitation method","volume":"6","author":"Papdiwal","year":"2014","journal-title":"Der Pharma Chem."},{"issue":"13","key":"10.1016\/j.heliyon.2022.e09925_bib18","first-page":"469","article-title":"Neuro-AIDS: current status and challenges to antiretroviral drug therapy (ART) for its treatment","volume":"15","author":"Kakad","year":"2020","journal-title":"Curr. Drug Ther."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09925_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0168-3659(02)00211-0","article-title":"Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics","volume":"83","author":"Chorny","year":"2002","journal-title":"J.\u00a0Contr. Release"},{"issue":"4","key":"10.1016\/j.heliyon.2022.e09925_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1208\/s12249-012-9833-0","article-title":"Eudragit-based Nanosuspension of poorly water-soluble drug: formulation and in vitro\u2013in vivo evaluation","volume":"13","author":"Yadav","year":"2012","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09925_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future","volume":"47","author":"M\u00fcller","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2022.e09925_bib22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijbiomac.2014.03.022","article-title":"Donepezil Nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation","volume":"67","author":"Md","year":"2014","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09925_bib23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/03639045.2012.758130","article-title":"Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting","volume":"40","author":"Bhavna","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09925_bib24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1208\/s12249-010-9404-1","article-title":"Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir","volume":"11","author":"Sinha","year":"2010","journal-title":"AAPS PharmSciTech"},{"issue":"1-2","key":"10.1016\/j.heliyon.2022.e09925_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchromb.2004.10.005","volume":"813","author":"Dailly","year":"2004","journal-title":"J.\u00a0Chromatogr. B"},{"key":"10.1016\/j.heliyon.2022.e09925_bib26","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1080\/10717544.2016.1199605","article-title":"Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles","volume":"23","author":"Joshi","year":"2016","journal-title":"Drug Deliv."},{"issue":"12","key":"10.1016\/j.heliyon.2022.e09925_bib27","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1016\/j.actbio.2011.07.025","article-title":"Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies","volume":"7","author":"Seju","year":"2011","journal-title":"Acta Biomater."},{"issue":"1-2","key":"10.1016\/j.heliyon.2022.e09925_bib28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijpharm.2013.04.084","article-title":"Brain targeting of olanzapine via intranasal delivery of core\u2013shell difunctional block copolymer mixed nanomicellar carriers: in vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies","volume":"452","author":"Abdelbary","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.heliyon.2022.e09925_bib29","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11051-013-2043-1","article-title":"Nanosuspensions of 10-hydroxycamptothecin that can maintain high and extended supersaturation to enhance oral absorption: preparation, characterization and in vitro\/in vivo evaluation","volume":"15","author":"Pu","year":"2013","journal-title":"J.\u00a0Nanoparticle Res."},{"key":"10.1016\/j.heliyon.2022.e09925_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jddst.2017.10.001","article-title":"The impact of process parameters on carrier free paracetamol Nanosuspension prepared using different stabilizers by antisolvent precipitation method","volume":"43","author":"Shariare","year":"2018","journal-title":"J.\u00a0Drug Deliv. Sci. Technol."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e09925_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.apsb.2013.08.001","article-title":"Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain","volume":"3","author":"Prabhakar","year":"2013","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.heliyon.2022.e09925_bib32","first-page":"326","article-title":"Enhancement of dissolution rate of ritonavir: a comparative study using various carriers and techniques","volume":"9","author":"Sarada","year":"2015","journal-title":"Global J. Pharmacol."},{"issue":"6","key":"10.1016\/j.heliyon.2022.e09925_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.apsb.2014.10.005","article-title":"Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation","volume":"4","author":"Yasir","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09925_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2008-2231-21-27","article-title":"Design and evaluation of Lumefantrine\u2013Oleic acid self nanoemulsifying ionic complex for enhanced dissolution","volume":"21","author":"Patel","year":"2013","journal-title":"Daru"},{"issue":"7","key":"10.1016\/j.heliyon.2022.e09925_bib35","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/03639040802623941","article-title":"Preparation of fenofibrate Nanosuspension and study of its pharmacokinetic behavior in rats","volume":"35","author":"Li","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09925_bib36","unstructured":"Reddy BP, Reddy KR, Reddy RR, Reddy DM, Reddy KSC, Hetero Res Foundation, 2013. U.S. Patent 8,445,506."},{"key":"10.1016\/j.heliyon.2022.e09925_bib37","unstructured":"Morissette SL, Almarsson O, Soukasene S, TransForm Pharmaceuticals Inc. 2007 U.S. Patent 7,205,413."},{"issue":"1-2","key":"10.1016\/j.heliyon.2022.e09925_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2010.11.009","article-title":"Preparation of a chemically stable quercetin formulation using Nanosuspension technology","volume":"404","author":"Gao","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.heliyon.2022.e09925_bib39","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3109\/03639041003695139","article-title":"Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin Nanosuspension with TPGS as stabilizer","volume":"36","author":"Gao","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09925_bib40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0168-3659(00)00367-9","article-title":"Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation","volume":"70","author":"Redhead","year":"2001","journal-title":"J.\u00a0Contr. Release"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09925_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/j150523a014","article-title":"Tracer electrophoresis. II. The mobility of the micelle of sodium lauryl sulfate and its interpretation in terms of zeta potential and charge","volume":"59","author":"Stigter","year":"1955","journal-title":"J.\u00a0Phys. Chem."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09925_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsps.2015.03.008","article-title":"Enhanced ex vivo intestinal absorption of olmesartan medoxomil Nanosuspension: preparation by combinative technology","volume":"24","author":"Attari","year":"2016","journal-title":"Saudi Pharmaceut. J."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e09925_bib43","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/jps.2600740511","article-title":"Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats","volume":"74","author":"Ohwaki","year":"1985","journal-title":"J.\u00a0Pharmaceut. Sci."},{"issue":"1-2","key":"10.1016\/j.heliyon.2022.e09925_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0378-5173(02)00040-6","article-title":"Buparvaquone mucoadhesive Nanosuspension: preparation, optimisation and long-term stability","volume":"237","author":"M\u00fcller","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09925_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13204-012-0188-3","article-title":"Nanosuspension for enhancement of oral bioavailability of felodipine","volume":"4","author":"Sahu","year":"2014","journal-title":"Appl. Nanosci."},{"key":"10.1016\/j.heliyon.2022.e09925_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejpb.2015.08.008","article-title":"Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: role of docosahexaenoic acid","volume":"96","author":"Shinde","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09925_bib47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejpb.2004.03.022","article-title":"Development of an intravenously injectable chemically stable aqueous omeprazole formulation using Nanosuspension technology","volume":"58","author":"M\u00f6schwitzer","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022012130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022012130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T22:17:23Z","timestamp":1755555443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844022012130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2405844022012130"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09925","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nose to brain delivery of nanosuspensions with first line antiviral agents is alternative treatment option to Neuro-AIDS treatment","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e09925"}}